ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of Directors
SINGAPORE, April 11, 2023 /PRNewswire/ -- ACM Biolabs (FR0012596468 – ALSEN) a pioneering Singaporean-Swiss biotechnology company, which specializes in the development of targeted therapeutics for the prevention of multiple life-threatening diseases based on its proprietary ACM (Artificial Cell Membranes) tunable polymer-based delivery ATP™ technology, announces the appointment of David Lawrence as Non-Executive Director....
Read more